CD274 and pancreatic neoplasm: Combined treatment with a USP8 inhibitor and anti-PD-L1 therapy markedly inhibits pancreatic tumor growth, mediated through activation of cytotoxic T cells and the PD-L1/CD8+ T-cell axis.